H1 2026 Financial Results
Posted at h
in Announcements
Paiania, 17 September 2026 – The Lavipharm Group, during H1 2026, reported a significant increase in consolidated sales prior to clawback and rebate of 24.1%, while EBITDA from continuing operations increased by 5.2%.